去纤苷治疗SARS-CoV-2相关ARDS
这项前瞻性、开放标签、单中心安全性试验纳入12例有临床和影像学ARDS表现、无活动性出血、D-二聚体>2倍正常上限、SARS-CoV-2 PCR阳性的成人患者,给予去纤苷6.25 mg/kg/剂静注每6小时、计划7天,每日监测D-二聚体和呼吸功能。治疗期间无出血或血栓并发症,无归因于去纤苷的其他不良事件;4例达到第7天肺部反应参数者均在治疗最初72小时内D-二聚体下降。3例死于进行性肺病(入组后11、17、34天),9例(75%)在启动去纤苷后64至174天仍存活,30天全因死亡率17%(95%CI 0%-35%);基线PaO2/FiO2≥125 mmHg者全部存活,<125 mmHg的3例均死亡。作者认为去纤苷用于SARS-CoV-2相关ARDS安全可耐受,在这一历史死亡率高的人群中结果有前景。
要点
- 去纤苷6.25 mg/kg/剂静注每6小时、计划7天用于SARS-CoV-2相关ARDS,治疗期间无出血或血栓并发症,无归因于药物的其他不良事件。
- 12例中10例接受机械通气、6例接受血管升压药支持;30天全因死亡率17%(95%CI 0%-35%)。
- 4例达到第7天肺部反应参数,且均在去纤苷治疗最初72小时内血清D-二聚体下降。
- 基线PaO2/FiO2≥125 mmHg者全部存活,基线PaO2/FiO2<125 mmHg的3例均死亡。
- 9例(75%)在启动去纤苷后64至174天仍存活;3例死于进行性肺病,分别为入组后11、17、34天。
适用人群与场景
- 年龄18岁及以上、有ARDS临床和影像学表现、无活动性出血、血清D-二聚体>2倍正常上限、SARS-CoV-2 PCR阳性的成人患者。
- 研究入组时10例接受机械通气、6例接受血管升压药支持;中位年龄63岁。
诊断标准与关键阈值
- ARDS诊断依据临床和影像学表现;入组要求血清D-二聚体>2倍正常上限且SARS-CoV-2 PCR阳性。
- 基线PaO2/FiO2≥125 mmHg者全部存活,基线PaO2/FiO2<125 mmHg的3例均死亡。
处置流程与药物剂量
- 去纤苷6.25 mg/kg/剂静注每6小时,计划7天疗程,治疗期间每日监测血清D-二聚体和呼吸功能。
红旗征与不能漏的情况
- 入组要求无活动性出血征象。
研究设计与关键结果
- 前瞻性、开放标签、单中心安全性试验,共12例接受去纤苷治疗;中位年龄63岁,入组时10例接受机械通气、6例接受血管升压药支持,中位D-二聚体3.25 μg/ml(范围1.33-12.3)。
- 中位治疗持续时间7天;治疗期间无出血或血栓并发症,无归因于去纤苷的其他不良事件。
- 4例达到第7天肺部反应参数,4例均在去纤苷治疗最初72小时内血清D-二聚体下降。
- 3例死于进行性肺病,分别为入组后11、17、34天;9例(75%)在启动去纤苷后64至174天仍存活。
- 第30天全因死亡率17%(95%CI 0%-35%);基线PaO2/FiO2≥125 mmHg者全部存活,基线PaO2/FiO2<125 mmHg的3例均死亡。
证据类型、等级与局限
- 证据类型:前瞻性、开放标签、单中心安全性试验;试验注册号ClinicalTrials.gov NCT04530604。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为去纤苷用于SARS-CoV-2相关ARDS安全可耐受,治疗期间无出血或血栓并发症,在这一历史死亡率高的人群中结果有前景。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: SARS-CoV-2-related ARDS is associated with endothelial dysfunction and profound dysregulation of the thrombotic-fibrinolytic pathway. Defibrotide is a polyanionic compound with fibrinolytic, antithrombotic, and antiinflammatory properties.
RESEARCH QUESTION: What is the safety and tolerability of defibrotide in patients with severe SARS-CoV-2 infections?
STUDY DESIGN AND METHODS: We report a prospective, open-label, single-center safety trial of defibrotide for the management of SARS-CoV-2-related ARDS. Eligible participants were 18 years of age or older with clinical and radiographic signs of ARDS, no signs of active bleeding, a serum D-dimer of more than twice upper limit of normal, and positive polymerase chain reaction-based results for SARS-CoV-2. Defibrotide (6.25 mg/kg/dose IV q6h) was administered for a planned 7-day course, with serum D-dimer levels and respiratory function monitored daily during therapy.
RESULTS: Twelve patients (median age, 63 years) were treated, with 10 patients receiving mechanical ventilation and 6 receiving vasopressor support at study entry. The median D-dimer was 3.25 μg/ml (range, 1.33-12.3) at study entry. The median duration of therapy was 7 days. No hemorrhagic or thrombotic complications occurred during therapy. No other adverse events attributable to defibrotide were noted. Four patients met the day 7 pulmonary response parameter, all four showing a decrease in serum D-dimer levels within the initial 72 h of defibrotide therapy. Three patients died of progressive pulmonary disease 11, 17, and 34 days after study entry. Nine patients (75%) remain alive 64 to 174 days after initiation of defibrotide. Day 30 all-cause mortality was 17% (95% CI, 0%-35%). All patients with a baseline Pao2 to Fio2 ratio of ≥ 125 mm Hg survived, whereas the three patients with a baseline Pao2 to Fio2 ratio of < 125 mm Hg died.
INTERPRETATION: The use of defibrotide for management of SARS-CoV-2-related ARDS proved safe and tolerable. No hemorrhagic or thrombotic complications were reported during therapy, with promising outcomes in a patient population with a historically high mortality rate.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04530604; URL: www.
CLINICALTRIALS: gov.
参考来源
- Frame D, Scappaticci GB, Braun TM, et al. Defibrotide Therapy for SARS-CoV-2 ARDS. Chest. 2022. PMID: 35413279. doi:10.1016/j.chest.2022.03.046
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。